Navigation Links
NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
Date:11/4/2010

PARK CITY, Utah, Nov. 4, 2010 /PRNewswire/ -- NuView Life Sciences, Inc ("NuView"), a biopharmaceutical company specializing in the development of proprietary target specific biomarkers for utilization with Positron Emission Tomography ("PET") imaging procedures, announced today that its applications for the Qualifying Therapeutic Discovery Project Credit ("Therapeutic Credit") were approved.

The grants totaling just over $1.2 million dollars were awarded to NuView for further development and validation of several of the Company's projects. The diagnostic imaging biomarker projects that were approved under the Therapeutic Credit program are for breast cancer, lymphoma, cancer proliferation and cardiovascular imaging.

"We are very pleased that the underlying science of our pipeline candidates has been recognized under the Therapeutic Credit program, further enabling the clinical advancement of these projects," commented Paul Crowe, Chairman and Chief Executive Officer of NuView.

About the Qualifying Therapeutic Discovery ProjectThe Qualifying Therapeutic Discovery Project tax credit or grant is provided under new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). The tax credit or grant is a benefit targeted to therapeutic discovery projects that show a reasonable potential to:

  • Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions;
  • Reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years.

  • Allocation of the credit or grant also takes into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences. The credit or grant is only available to companies with no more than 250 employees. The total amount of credits available to all companies is limited to $1 billion.

    About NuView Life Sciences, IncNuView Life Sciences, Inc is a privately held Utah based biopharmaceutical company developing target specific biomarkers for diagnostic Positron Emission Tomography ("PET") imaging procedures. The Company's clinical stage pipeline includes several proprietary products for diagnosing cancer and heart disease.  Please visit our website at www.nuviewinfo.com.For more information please contact:

    Rob Alday NuView Life Sciences, IncTel.  435-647-9758Fax. 435-647-5602info@nuviewinfo.com
    '/>"/>

    SOURCE NuView Life Sciences, Inc
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
    2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
    3. Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions
    4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
    5. Pittsburgh Life Sciences Greenhouse and Innovation Works Announce Investments in Ib2C™
    6. Indiana Life Sciences Start Ups Garner More than $1.5 Million in Competitive Federal Funding
    7. Neurocrine Biosciences Reports Third Quarter 2010 Results
    8. Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    9. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
    10. Caliper Life Sciences Signs Co-Marketing Pact with Illumina to Improve Sequencing Workflows
    11. Caliper Life Sciences Expands Offering for Next Generation Sequencing Workflows
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
    (Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
    (Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
    Breaking Medicine Technology:
    (Date:5/2/2016)... ... 2016 , ... WestHarbor Growth Partners, a growth, expansion and ... Grow Healthy Vending’s newly revamped brand campaign. Grow Healthy Vending is headquartered ... in North America with locations across the United States as well as internationally. ...
    (Date:5/2/2016)... New York, NY (PRWEB) , ... May 02, 2016 , ... ... Highlighting the year’s best in pet gear and toys, leading product review site ... TTPM Pets Paw of Excellence Awards at their Spring Showcase at the Metropolitan ...
    (Date:5/2/2016)... Illinois (PRWEB) , ... May 02, 2016 , ... MedPro ... modernized mail back service. MedPro now offers its mail back service for an ... offer; we are now able to provide service to all of the clients in ...
    (Date:5/2/2016)... ... May 02, 2016 , ... Further establishing itself as a leader ... new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants as a winner ... , WHIMZEES natural dental chews for dogs are a favorite product among pet-parents worldwide, ...
    (Date:5/2/2016)... , ... May 02, 2016 , ... Dr. Rassouli, ... health and cognitive decline. According to the research, which was published in the “Journal ... of cognitive decline, and about 5.4 million Americans have Alzheimer’s disease. The study found ...
    Breaking Medicine News(10 mins):